Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sens. Clinton, Murray Question FDA Timing On Plan B In Letter To Leavitt

This article was originally published in The Pink Sheet Daily

Executive Summary

Letter to HHS Secretary notes FDA announced concerns about dual status marketing of Plan B more than one year after receiving the proposal from Barr.

You may also be interested in...



FDA Approps Bill Debate Could Include “Controversial Amendments,” Sen. Hatch Says

Amendments on drug importation, Plan B and follow-on biologics could be brought to the Senate floor during debate on the Agriculture appropriations measure.

FDA Approps Bill Debate Could Include “Controversial Amendments,” Sen. Hatch Says

Amendments on drug importation, Plan B and follow-on biologics could be brought to the Senate floor during debate on the Agriculture appropriations measure.

FDA Women’s Health Director Resigns Over Plan B

Susan Wood says she can “no longer serve as staff when scientific and clinical evidence...has been overruled.”

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel